In this article, we discuss the 5 biotech penny stocks to invest in. If you want to read our detailed analysis of these stocks, go directly to 12 Best Biotech Penny Stocks to Invest In.
5. Ocean Biomedical, Inc. (NASDAQ:OCEA)
Number of Hedge Fund Holders: 5
Ocean Biomedical, Inc. (NASDAQ:OCEA) is a biopharmaceutical company that focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme.
At the end of the fourth quarter of 2023, 5 hedge funds in the database of Insider Monkey held stakes worth $406,000 in Ocean Biomedical, Inc. (NASDAQ:OCEA), compared to 4 in the preceding quarter worth $726,000.
4. VBI Vaccines Inc. (NASDAQ:VBIV)
Number of Hedge Fund Holders: 5
VBI Vaccines Inc. (NASDAQ:VBIV) is a Massachusetts-based biopharma company founded in 1965. VBI Vaccines Inc. (NASDAQ:VBIV) develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Perceptive Advisors is a leading shareholder in VBI Vaccines Inc. (NASDAQ:VBIV) with 1.3 million shares worth more than $814,000.
At the end of the fourth quarter of 2023, 5 hedge funds in the database of Insider Monkey held stakes worth $1.2 million in VBI Vaccines Inc. (NASDAQ:VBIV), compared to 4 in the previous quarter worth $1.4 million.
3. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)
Number of Hedge Fund Holders: 6
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) is a Boston-based biotechnology company founded in 2000. Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. A lead respiratory Anticalin-based drug candidate is elarekibep. It is used for the treatment of asthma.
At the end of the fourth quarter of 2023, 6 hedge funds in the database of Insider Monkey held stakes worth $5.9 million in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), compared to 7 in the preceding quarter worth $10 million.
Among the hedge funds being tracked by Insider Monkey, California-based investment firm Lynx1 Capital Management is a leading shareholder in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) with 9.7 million shares worth more than $1.7 million.
2. Leap Therapeutics, Inc. (NASDAQ:LPTX)
Number of Hedge Fund Holders: 10
Leap Therapeutics, Inc. (NASDAQ:LPTX) is a biopharma firm focusing on the development of treatments for cancer. In late November, investment advisory Mizuho maintained a Buy rating on Leap Therapeutics, Inc. (NASDAQ:LPTX) stock and lowered the price target to $12 from $20.
At the end of the fourth quarter of 2023, 10 hedge funds in the database of Insider Monkey held stakes worth $21 million in Leap Therapeutics, Inc. (NASDAQ:LPTX), the same as in the preceding quarter worth $7.8 million.
Among the hedge funds being tracked by Insider Monkey, New York-based investment firm Baker Bros. Advisors is a leading shareholder in Leap Therapeutics, Inc. (NASDAQ:LPTX) with 1.1 million shares worth more than $4.8 million.
1. Emergent BioSolutions Inc. (NYSE:EBS)
Number of Hedge Fund Holders: 15
Emergent BioSolutions Inc. (NYSE:EBS) is a life sciences company that provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose, as well as the Vaxchora vaccine for the prevention of cholera.
Among the hedge funds being tracked by Insider Monkey, New Jersey-based investment firm Millennium Management is a leading shareholder in Emergent BioSolutions Inc. (NYSE:EBS) with 2 million shares worth more than $5 million.
At the end of the fourth quarter of 2023, 15 hedge funds in the database of Insider Monkey held stakes worth $16 million in Emergent BioSolutions Inc. (NYSE:EBS), the same as in the preceding quarter worth $26 million.
You can also take a peek at 20 Most Owned Stocks by Hedge Funds Now and 11 Fastest Growing AI Stocks To Invest In Now.
